The scale of the problem is growing as populations age and the prevalence of obesity, hypertension, diabetes and chronic kidney disease rises. In the United States, total medical costs associated with heart failure are projected to exceed $70 billion by 2030. The condition already affects approximately 22 percent of people with type 2 diabetes—more than one in five patients. Diabetes itself is considered stage A heart failure under the contemporary staging system, meaning that it places a person at increased risk even in the absence of symptoms or detectable structural heart disease. That risk is amplified by high blood pressure, excess adiposity, coronary disease, smoking and impaired kidney function. The experts describe these conditions not as isolated diagnoses but as interconnected components of cardiovascular-kidney-metabolic syndrome, in which disturbances in glucose regulation, vascular biology, renal filtration and cardiac function reinforce one another.

Heart failure is not a single mechanical failure in which the heart simply stops pumping. It is a clinical syndrome in which the heart cannot meet the body’s demands without elevated filling pressures, leading to symptoms, fluid accumulation and progressive organ dysfunction. The disease is divided into stages that describe its evolution. Stage A includes people at risk, including those with type 2 diabetes but no symptoms. Stage B, often called pre-heart failure, refers to people who have structural or functional abnormalities of the heart or abnormal cardiac biomarkers without symptoms. Stage C is symptomatic heart failure, while stage D represents advanced disease, in which symptoms interfere with daily activities and hospitalizations may occur repeatedly. By the time a patient reports shortness of breath, ankle swelling or obvious congestion, the disease may already have crossed into stage C.

The clinical challenge is that early heart failure can look remarkably ordinary. Fatigue, reduced exercise capacity, breathlessness and swelling can be attributed to aging, obesity, chronic obstructive pulmonary disease, venous insufficiency, kidney disease or deconditioning. In people with multiple medical conditions, clinicians may have difficulty identifying which diagnosis is driving a change in symptoms. Heart failure is consequently missed or misdiagnosed, particularly in patients who also have lung disease or ischemic heart disease. An apparently simple complaint such as leg edema can reflect increased venous pressure caused by cardiac dysfunction, but it can also arise from cirrhosis, nephrotic syndrome, thyroid disease or chronic venous disease. The commentary argues that the first safeguard is a deliberate medical history and physical examination that treats these symptoms as possible clues to cardiac disease rather than automatically assigning them to a familiar comorbidity.

The authors also emphasize that heart failure associated with diabetes frequently occurs even when the heart’s pumping percentage appears normal. Clinicians classify heart failure partly by left ventricular ejection fraction, the proportion of blood expelled from the main pumping chamber with each contraction. Heart failure with reduced ejection fraction, or HFrEF, is defined by an ejection fraction of 40 percent or less. Heart failure with preserved ejection fraction, or HFpEF, generally involves an ejection fraction of at least 50 percent, while values between 40 and 50 percent fall into an intermediate category. In HFpEF, the ventricle may contract sufficiently but become stiff, preventing it from relaxing and filling normally. The resulting rise in pressure can force fluid backward into the lungs and tissues. Diabetes, obesity, hypertension and kidney disease are strongly associated with this form of heart failure, meaning that a “normal” ejection fraction does not rule out serious cardiac dysfunction.

For patients at elevated risk, the experts highlight blood tests that can reveal cardiac stress before severe symptoms develop. Natriuretic peptides—principally B-type natriuretic peptide, or BNP, and its inactive precursor N-terminal pro-BNP, or NT-proBNP—are released when the heart muscle is stretched by pressure or volume overload. BNP is produced from a precursor molecule and acts hormonally, promoting the excretion of sodium and water and encouraging blood-vessel relaxation; NT-proBNP is biologically inactive but remains useful because its concentration reflects the same underlying stress. The commentary identifies BNP levels above 50 picograms per milliliter and NT-proBNP levels above 125 picograms per milliliter as useful risk thresholds, while high-sensitivity cardiac troponin above the 99th percentile for a healthy population may indicate myocardial injury or stress. The authors recommend at least annual measurement of a natriuretic peptide or high-sensitivity troponin in high-risk patients, with more frequent testing when clinical status changes.

These biomarkers are not crystal balls, and their interpretation requires physiological context. NT-proBNP and BNP can rise with age, atrial fibrillation and chronic kidney disease even when worsening heart failure is not the immediate cause. Reduced kidney filtration slows the removal of circulating molecules and reflects broader changes in fluid balance and vascular health. Conversely, obesity can suppress natriuretic peptide concentrations, potentially masking significant cardiac dysfunction and producing a deceptively reassuring result. For that reason, the experts caution against treating a single laboratory value as a diagnosis. Trends may be more informative than isolated measurements. In the EXAMINE trial, which included people with type 2 diabetes, two NT-proBNP measurements taken six months apart helped distinguish risk: patients with persistently elevated values had the greatest likelihood of developing heart failure, while an increase from baseline was itself associated with rising risk. Serial testing effectively turns a snapshot into a trajectory.

When biomarkers or symptoms raise concern, echocardiography is the next important investigation. An echocardiogram uses ultrasound waves to generate moving images of the heart, allowing clinicians to assess chamber size, wall motion, valve function, filling patterns and pumping performance. It can reveal structural remodeling caused by long-standing hypertension, evidence of prior ischemic injury or abnormalities consistent with diabetic cardiomyopathy. It also helps distinguish HFrEF from HFpEF and can identify conditions that require different treatment strategies. The clinicians do not recommend echocardiography for every person with diabetes solely because diabetes confers risk. Rather, they describe a targeted sequence: identify high-risk patients, examine them carefully, measure biomarkers and arrange imaging when results or clinical findings suggest cardiac dysfunction. Importantly, they stress that potentially beneficial intervention should not necessarily be postponed while waiting for an echocardiogram, particularly when the overall clinical picture is compelling.

Risk-prediction tools such as the TIMI Heart Failure Risk Score and the Health ABC Heart Failure Risk Model may help clinicians understand how age, diabetes, hypertension and other variables combine to influence prognosis, but the specialists present them as aids rather than replacements for clinical judgment. The most urgent opportunity lies in the period before repeated decompensations, emergency visits and hospital admissions begin. Heart failure often has an initially stable phase followed by episodes in which fluid accumulates, symptoms worsen and the risk of hospitalization and death rises. Earlier recognition can lengthen the period of relative stability and preserve quality of life. The commentary therefore calls for a coordinated approach in which primary-care practices and diabetes clinics participate directly in cardiovascular surveillance. Patient conversations should explain why heart failure is being assessed, while prevention efforts address weight management, smoking cessation, physical activity and adherence to prescribed medication. The podcast’s later episodes are intended to discuss guideline-directed drug therapy and lifestyle modification, but the first episode’s message is that detection is the gateway to every subsequent intervention.

The experts’ appeal reflects a broader shift in cardiovascular medicine: diabetes care can no longer focus only on blood glucose, retinal disease, neuropathy and atherosclerotic events while treating heart failure as a specialist problem. The biological links between insulin resistance, inflammation, adipose-tissue dysfunction, arterial stiffening, renal injury and myocardial remodeling make heart failure a core complication of metabolic disease. A patient who appears stable in an endocrinology or primary-care waiting room may already have stage B disease, with changes that are detectable through biomarkers or imaging but not yet severe enough to cause obvious symptoms. Recognizing that hidden phase could be decisive, because treatment and risk-factor control are more likely to prevent deterioration before the heart enters a cycle of congestion and hospitalization. The commentary, developed by Desai, Inzucchi and Wright as the first installment of a clinical podcast series, does not report a new clinical trial or newly generated dataset. Instead, it translates existing evidence into an urgent clinical signal: in people with diabetes, the search for heart failure should begin before the heart failure announces itself.

Neutrophils are pivotal components of the immune system, and their response can indicate various inflammatory states. High-density lipoprotein cholesterol, often referred to as “good” cholesterol, plays a crucial role in lipid metabolism and cardiovascular health. The ratio of neutrophils to HDL-C could serve as a novel index, reflecting an individual’s inflammatory burden and metabolic health. This study posits that an elevated ratio might correlate with higher incidences of diabetes, presenting these findings in a manner that could shift clinical practices.

In the context of increasing diabetes prevalence globally, understanding the parameters that contribute to this metabolic disorder is imperative. Millions suffer from both type 1 and type 2 diabetes, creating a significant burden on healthcare systems. This study delineates a connection that could help identify individuals at risk of developing diabetes or those who may be facing dire health complications associated with the disease. Moreover, understanding how neutrophil and HDL-C levels interact offers insights into the underlying mechanisms of diabetes pathogenesis.

The researchers conducted their study on a substantial demographic, gathering data to analyze the significance of the neutrophil-to-HDL-C ratio effectively. Utilizing robust statistical methodologies, the investigators were able to discern patterns that indicate elevated ratios link to poorer metabolic profiles. Furthermore, the study takes into account confounding factors that could have skewed results, ensuring that observations regarding diabetes prevalence are reliable and valid.

One of the most compelling aspects of the study is its focus on mortality associated with diabetes. Historically, linking biomarkers to mortality has been challenging. However, this research suggests that patients exhibiting a high neutrophil-to-HDL-C ratio face increased risks of mortality, emphasizing the need for proactive monitoring of these values in diabetic patients. Understanding this correlation could ultimately enhance preventive strategies and patient outcomes.

The findings presented in this study call into question the traditional approaches toward assessing cardiovascular risks in diabetic patients. The implications extend beyond mere correlation; they suggest a direct pathway by which neutrophils and HDL-C could influence metabolic processes. This forms the basis for further investigations and perhaps clinical trials aimed at modulating these parameters to better control diabetes and its complications.

The aspect of inflammation in diabetes is not a new topic; however, the unique angle taken by the researchers provides a fresh perspective. By framing the discussion around a simple blood test that reveals the neutrophil-to-HDL-C ratio, there lies an opportunity for healthcare providers to integrate this into routine assessments. Such integration could make a significant difference in managing complications and improving quality of life for patients with diabetes.

In the tailwind of these findings, future research will likely explore therapeutic avenues to manipulate these ratios effectively. Could dietary interventions aimed at increasing HDL-C or reducing neutrophil counts yield beneficial effects on diabetic patients? These are the questions that researchers may delve into, driving the field forward. As diabetes continues to pose a challenge globally, the search for solutions becomes ever more critical.

Moreover, the comprehensive nature of the study is noteworthy. By inclusively analyzing various demographics, the findings offer generalizability that can benefit diverse populations across different geographic and socio-economic landscapes. The versatility of the neutrophil-to-HDL-C ratio as a biomarker means it could find its place in routine screening protocols and expand access to preventive care efforts.

This study emphasizes the interconnectedness of systemic inflammation and metabolic disorders. As more clinicians appreciate the relevance of these findings, there may be a paradigm shift in how diabetes and its accompanying risks are approached. The potential for improving patient care through awareness and understanding of this biomarker cannot be overstated and could herald a new age of predictive medicine.

In conclusion, the compelling evidence presented by Tao et al. opens the door to rethinking diabetes management strategies and tools. With the integration of neutrophil-to-HDL-C ratios into clinical practice, the healthcare landscape could evolve, ultimately leading to enhanced patient outcomes and reduced mortality rates associated with diabetes. The call to action lies with the medical community to embrace this insight and translate it into clinical practice, ensuring that patients receive the most informed and effective care possible.

As this research paves the way for future studies, it signifies the importance of continuous investigation into the relationships between biomarkers and diseases. Particularly, the interplay between inflammatory markers and chronic conditions like diabetes remains a fertile ground for discovery and innovation. The emerging knowledge will help inform clinical guidelines, patient education, and future investigations into viable therapeutic interventions aimed at improving the lives of those affected by diabetes.

The journey to unraveling diabetes’s complexities does not end with this study. It serves as a crucial step toward understanding how monitoring the neutrophil-to-HDL-C ratio could potentially change the landscape of diabetes management for better health outcomes across populations.

Subject of Research: Association between neutrophil-to-high-density lipoprotein-cholesterol ratio and prevalence and mortality of diabetes.

Article Title: Association between neutrophil-to-high-density lipoprotein-cholesterol ratio and prevalence and mortality of diabetes: a cross-sectional study.

Article References:

Tao, Y., Liu, Y., Guo, S. et al. Association between neutrophil-to-high-density lipoprotein-cholesterol ratio and prevalence and mortality of diabetes: a cross-sectional study.
BMC Endocr Disord 25, 163 (2025). https://doi.org/10.1186/s12902-025-01978-1

Image Credits: AI Generated

DOI: 10.1186/s12902-025-01978-1

Keywords: Neutrophil-to-HDL-C ratio, diabetes prevalence, diabetes mortality, biomarkers, inflammation, metabolic health.